Lotus

What Lotus does

Lotus Pharmaceutical (TWSE: 1795) is a Taiwan-headquartered specialty pharmaceutical company founded in 1966 that develops, manufactures, in-licenses, and commercializes high-barrier generic, branded, 505(b)(2), biosimilar, and new chemical entity (NCE) medicines across oncology and immunology, CNS, women's health, primary care, and nephrology therapeutic areas. Following the December 2025 acquisition of Alvogen US — which provided a fully integrated US operating base with R&D, manufacturing, and commercial functions — Lotus is now positioned as a Top 20 Global Specialty Pharmaceutical Company with 250+ commercial products marketed across 90+ markets and 80+ R&D pipeline projects. Manufacturing sites are certified by US FDA, EU EMA, Japan PMDA, China NMPA, and Brazil ANVISA, and the firm was the first in Taiwan to gain FDA approval for a softgel dosage form.

Revenue is generated through multiple streams: direct commercialization via wholly-owned subsidiaries (Alvogen Korea, Alvogen Pharma US / Norwich Pharmaceuticals, Taiwan operations), in-licensing and out-licensing deals (265+ licensing agreements signed, 100+ global partnerships), hospital formulary and retail pharmacy distribution, and B2B partnerships with regional distributors. H1 2026 consolidated revenue reached NT$17,453M (~US$545M), up 84% YoY, with the US contributing ~62%, Asia ~30%, and B2B ~8%. The portfolio includes complex generics (Lenalidomide, Gefitinib, Bostini/bosutinib, Enzalutamide, Nintedanib, Vinorelbine softgel capsules, Baloxavir Marboxil), in-licensed brands (Alimta, Cialis, Mercilon, SERPLUMA, Uro-Vaxom), biosimilars (Alymsys, Denosumab, Darbepoetin), and pipeline assets including LP757 (cabozantinib, FDA NDA accepted July 2026 via 505(b)(2) pathway) and a Keytruda biosimilar candidate (FYB206).

Lotus pursues a hybrid portfolio strategy balancing in-house R&D (formulation development centers in India, Norwich Clinical Services in Bangalore for BA/BE and clinical trials) with strategic business development including M&A (Sandoz Philippines announced, Teva Thailand and Alpha Choay from Sanofi completed in 2022) and licensing partnerships (Henlius for SERPLUMA, OM Pharma for Uro-Vaxom). The company is publicly listed on the Taiwan Stock Exchange, led by Chairman Róbert Wessman and CEO Petar Vazharov, and operates across North America, Europe, and Asia-Pacific with an expanding Southeast Asia footprint.

Name

Lotus

Legal name

Lotus Pharmaceutical Co., Ltd.

Website

https://lotuspharm.com

Company type

Public

Founded year

1966

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Lotus Pharmaceutical is a Taiwan-headquartered specialty pharmaceutical company that develops, manufactures, and commercializes generic, branded, biosimilar, and NCE medicines across oncology, immunology, CNS, women's health, and nephrology in 90+ global markets.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Biologics & Biosimilars Distributors (HLAIAJAH), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Specialty pharmaceuticals
• Generic drug development
• Oncology therapeutics
• Biosimilar manufacturing
• Pharmaceutical licensing

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceuticals: Commercialization of complex generic drugs with focus on oncology and immunology. Products include Lenalidomide, Gefitinib, Vinorelbine softgel capsules, Bosutinib, Enzalutamide, and Nintedanib. Revenue generated through direct sales in major markets and B2B licensing to regional partners.
2. Branded Medicines: In-licensing and commercialization of tail-end branded medicines acquired from major pharmaceutical companies. Portfolio includes Alimta (oncology), Cialis (primary care), Mercilon (women's health), Aclasta, Evista, and Kalimate (nephrology). Revenue generated through direct commercialization in regional markets.
3. 505(b)(2) Products: Leveraging 505(b)(2) regulatory pathway to accelerate development of differentiated drug products including Qsymia (anti-obesity) in Korea and LP757 (cabozantinib) via 505(b)(2) NDA accepted by FDA.
4. Biosimilars: Development and commercialization of biosimilar products including Alymsys (oncology), Denosumab (women's health), and Darbepoetin (nephrology) through strategic partnerships.
5. NCE Pipeline: Novel chemical entity development including Zepzelca and Alyssa for oncology and women's health therapeutic areas, with revenue potential upon regulatory approval.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Lotus Pharmaceutical develops, manufactures, in-licenses, and commercializes specialty pharmaceutical products across five therapeutic areas: oncology & immunology, CNS, women's health, primary care, and nephrology. The portfolio spans generics (Lenalidomide, Bostini, Enzalutamide, Nintedanib), in-licensed brands (Alimta, Cialis, Uro-Vaxom), 505(b)(2) products (LP757/cabozantinib, Qsymia), biosimilars (Alymsys, Denosumab, Darbepoetin), and novel chemical entities (Zepzelca, Alyssa), with 250+ commercial products sold across 90+ global markets through direct operations and licensing partnerships.

Product overview

Lotus is a Top 20 Global Specialty Pharmaceutical Company offering a differentiated portfolio across five therapeutic areas: oncology & immunology, CNS, women's health, primary care & lifestyle, and nephrology. The portfolio includes: (1) Generics - complex generics with focus on oncology such as Lenalidomide, Bosutinib (Bostini), Enzalutamide, Nintedanib, Vinorelbine softgel capsules; (2) Brands - in-licensed medicines including Alimta, Cialis, Qsymia; (3) 505(b)(2) products including LP757 (cabozantinib); (4) Biosimilars including Alymsys, Denosumab, Darbepoetin; (5) NCEs including Zepzelca and Alyssa. The company operates 80+ R&D pipelines and 300+ commercial products across 90+ markets globally. Norwich Clinical Services provides CRO services for bioequivalence studies and clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• Alvogen Korea: Korean affiliate and wholly owned subsidiary of Lotus Pharmaceutical, one of the leading pharmaceutical companies in South Korea with strong positions in oncology and respiratory diseases
• Alvogen
• Almatica (Brands)
• Almaject (Injectables)
• Hellow

Products and services

• Generics Portfolio

Quantifiable outcome

• 14% revenue CAGR (2015-2025)
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, strategic and pipeline.

• OM PharmacoreStrategic or Co-development Partner · 7 July 2026Acquisition agreement for Uro-Vaxom product rights in South Korea. Alvogen Korea assumed distribution responsibility effective July 1, 2026, with marketing authorization transfer expected Q4 2026. OM Pharma is headquartered in Geneva, Switzerland with products in 100 countries.
• Shanghai Henlius BiotechcoreStrategic or Co-development Partner · 2 July 2026Exclusive licensing agreement where Alvogen Korea (wholly-owned subsidiary) holds exclusive commercialization rights and co-exclusive development rights for SERPLUMA (serplulimab) in South Korea. Henlius developed the humanized anti-PD-1 monoclonal antibody; MFDS approval secured for first-line ES-SCLC treatment.
• Alvogen US (Acquisition)coreStrategic or Co-development Partner · 3 December 2025Completed acquisition of Alvogen US creating top 20 global specialty pharma powerhouse. Transaction includes fully integrated US operating base enhancing capabilities across R&D, manufacturing, commercial operations, legal, and regulatory affairs. Includes subsidiaries Alvogen (Generics), Almatica (Brands), Almaject (Injectables), and Norwich Pharmaceuticals.
• Petroleum Authority of Thailand (PTT)strategicStrategic or Co-development Partner · 1 January 2020Strategic partnership established in 2020 with PTT investing in Lotus, creating partnership in Southeast Asian pharmaceutical markets including Thailand operations.
• Alvogen (Asian operations merger)coreStrategic or Co-development Partner · 1 January 2014Lotus and Alvogen merged Asian operations in 2014, combining manufacturing and commercial capabilities in Asia-Pacific region.
• SandozstrategicStrategic or Co-development PartnerAcquisition of Sandoz's Philippines business to expand Lotus footprint in Southeast Asia, enhancing commercial platform and access to hospital and specialty care channels. Expected completion Q2 2026.
• FYB206 (Keytruda biosimilar candidate)pipelineStrategic or Co-development PartnerPartnership expanding oncology portfolio through FYB206, a Keytruda (pembrolizumab) biosimilar candidate under development.
• SLX-100 (orphan drug candidate)pipelineStrategic or Co-development PartnerPartnership for SLX-100, an orphan drug candidate for spinocerebellar ataxia type 27B, expanding rare disease portfolio.
• Eli Lilly (Asset acquisition)strategicStrategic or Co-development PartnerAcquisition of Alimta and Cialis from Eli Lilly for Taiwan market, expanding branded medicines portfolio in oncology and primary care.
• Sanofi (Asset acquisition)strategicStrategic or Co-development PartnerAcquisition of Alpha Choay from Sanofi for Vietnam market, strengthening branded medicines presence in Southeast Asia.
• Teva Pharma Thailand (Acquisition)strategicStrategic or Co-development PartnerAcquisition of Teva Pharma Thailand in 2025, expanding generics manufacturing and commercial footprint in Thailand.

Scale indicators22 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Hikma Pharmaceuticals: Hikma is a UK-headquartered specialty/generic pharma with comparable scale and product mix spanning generics, branded generics, and injectables. Operates across similar geographies including MENA, US, and Europe with analogous complex generics focus.
• Viatris: Viatris (formed from Mylan + Upjohn) is a global specialty/generic pharma with comparable portfolio of generics, branded generics, complex generics, and biosimilars across similar therapeutic areas and geographies.
• Sandoz: Sandoz is Novartis's former generics and biosimilars division, recently spun off as an independent specialty/generic pharma with comparable portfolio of generics, biosimilars, and specialty pharmaceuticals. Similar global footprint and therapeutic area focus.
• Endo International: Endo is a US-based specialty/generic pharmaceutical company with comparable focus on specialty pharmaceuticals, complex generics, and branded specialty products across similar therapeutic areas including oncology and specialty care.
• Dr. Reddy's Laboratories: Dr. Reddy's is an India-based global pharmaceutical company with strong focus on complex generics, biosimilars, and specialty pharmaceuticals, including oncology. Comparable hybrid model of in-house R&D and partnerships across US, Europe, and emerging markets.
• Cipla: Cipla is one of India's largest specialty/generic pharmaceutical companies with comparable global footprint, complex generics capability, and portfolio diversification across respiratory, oncology, and specialty therapeutics.
• Lupin Pharmaceuticals: Lupin is an India-headquartered specialty/generic pharma with comparable focus on complex generics, biosimilars, and specialty products. Operates in similar therapeutic areas and geographies including US, India, and emerging markets.
• Aurobindo Pharma: Aurobindo is an India-based global generic and specialty pharmaceutical company with substantial biosimilars portfolio, comparable scale, and similar strategic focus on complex generics and global market expansion including US and Europe.

Regional players

• Yuhan Corporation: Yuhan is South Korea's largest pharmaceutical company with comparable specialty/generic pharmaceutical portfolio across oncology, primary care, and specialty therapeutics. Operates regionally with similar focus on domestic Korean and select APAC markets rather than competing globally in the same footprint as Lotus.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical company and a leading specialty pharma with broad portfolio of generics, specialty, and biosimilars. As a broad incumbent, Teva competes with Lotus in complex generics and specialty oncology while offering wider geographic and therapeutic coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@lotuspharma4085
• LinkedInlinkedin.com/company/lotus-support-services-srl

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lotus